Cost & Coverage
Navigating Coverage Eligibility
3 steps to find information on coverage and savings
On WegovyCoverage.com, you will be able to find out your patient’s coverage and estimated out-of-pocket costs in minutes
You will be able to:
- Check your patient’s coverage status in minutes*
- Estimate your patient’s co-pay amount even if a prior authorization (PA) is required†
- Find restriction requirements and deductible information
- Check your patient’s eligibility for savings
*If online benefit verification does not provide information on coverage, you can submit a Service Request Form. The NovoCare® team will conduct a benefit investigation and follow up with coverage and cost details.
†If there is no co-pay amount listed and a PA is requested, this means your patient has coverage, but the co-pay amount is unknown.
Once you have verified your patient’s benefits, then you can initiate the prior authorization process
Novo Nordisk collaborates with CoverMyMeds to offer you a convenient way to navigate the prior authorization (PA) process.
You can initiate a PA by visiting WegovyCoverage.com or accessing an existing no-cost covermymeds.com account or creating a new one:
Visit covermymeds.com
Call 1-866-452-5017
Benefits include:
- Process requests for any medication and all plans
- Submit PA renewals from previously submitted requests
- Receive faster PA determinations, often in real time
- Offer appeal assistance, if needed
Once the PA is approved, your patients are ready to fill out their Wegovy™ prescription
Ask your patients to download the savings offer on SaveOnWegovy.com
Patients paying $25 who may need to temporarily step back their dose could pay as little as $0 for an additional 28-day supply by calling 1-833-4-Wegovy and pressing 2†
*Eligibility and restrictions apply. Subject to a maximum savings of $200 per 28-day supply. If patients pay cash for their prescriptions, they can save up to $200 per 28-day supply (1 box) of Wegovy™. Novo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at WegovyTerms.com.
†Eligibility and restrictions apply. For eligible commercially insured patients currently using a Wegovy™ savings offer, if such patients are prescribed a dose de-escalation within 21 days after the date of fill for the original dose. Subject to a maximum savings of $225 for up to a 28-day supply of Wegovy™. See terms and conditions at WegovyStepBack.com. Novo Nordisk reserves the right to modify or cancel this program at any time.
Learn more about benefit verification at novocare.com.
Your eligible patients could save on Wegovy™
Important Safety Information for Wegovy™ (semaglutide) injection 2.4 mg
WARNING: RISK OF THYROID C-CELL TUMORS
- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
- Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy™ and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy™
Indication and Usage
Wegovy™ (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
Limitations of Use
- Wegovy™ contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist
- The safety and effectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
- Wegovy™ has not been studied in patients with a history of pancreatitis
Important Safety Information cont.
Contraindications
- Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide
Warnings and Precautions
- Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
- Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart
- Acute Gallbladder Disease: In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy™-treated patients than in placebo-treated patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
- Hypoglycemia: Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes
- Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion
- Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist
- Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
- Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™
- Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation
Adverse Reactions
- The most common adverse reactions reported in ≥5% of patients treated with Wegovy™ are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease
Drug Interactions
- The addition of Wegovy™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
- Wegovy™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy™
Use in Specific Populations
- Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue Wegovy™. Discontinue Wegovy™ in patients at least 2 months before a planned pregnancy
Please click here for Wegovy™ Prescribing Information, including Boxed Warning.